- OLE study - Open Label Extension study phase Clarinet with lanreotide Autogel 120 mg in metastatic enteropancreatic neuroendocrine tumors2016 | First Faculty of Medicine
- Ralinepag Phase II Open-Label Extension Study in Patients with Pulmonary Arterial Hypertension2024 | Publication without faculty affiliation
- Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study2016 | First Faculty of Medicine
- Long-Term Safety, Tolerability and Survival in Patients with Pulmonary Arterial Hypertension Treated with Macitentan: Results from the SERAPHIN Open-Label Extension2022 | First Faculty of Medicine
- Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study2022 | First Faculty of Medicine
- Interim Analysis: Open-Label Extension Study of Leniolisib for Patients with APDS2024 | Second Faculty of Medicine
- Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study2021 | First Faculty of Medicine
- Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study2019 | First Faculty of Medicine
- Safety and efficacy of daclizumab in relapsing-remitting multiple sclerosis: 3-year results from the SELECTED open-label extension study2016 | First Faculty of Medicine
- Sebelipase alfa for lysosomal acid lipase deficiency: 5-year treatment experience from a phase 2 open-label extension study2020 | First Faculty of Medicine
- Safety and efficacy of deferiprone for pantothenate kinase-associated neurodegeneration : a randomised, double-blind, controlled trial and an open-label extension study2019 | First Faculty of Medicine
- Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5 years of follow-up in the DAYBREAK open-label extension trial2022 | First Faculty of Medicine
- Long-term safety and efficacy of daclizumab beta in relapsing-remitting multiple sclerosis: 6-year results from the SELECTED open-label extension study2020 | First Faculty of Medicine
- Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)2014 | Second Faculty of Medicine
- Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial2022 | Third Faculty of Medicine
- Long-term efficacy and safety of alpha 1 proteinase inhibitor treatment for emphysema caused by severe alpha 1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE)2017 | First Faculty of Medicine
- Long-term efficacy and safety adalimumab in children with juvenile rheumatoid arthritis (JRA): converting from body-surface-area dosing to weight-based fixed dosing in the open-label extension (OLE) of a phase III studyPublication without faculty affiliation
- Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension2018 | First Faculty of Medicine
- TEMPO 4:4 - multicentrická otevřená studie u autozomálně dominantní polycystické choroby ledvin hodnotící bezpečnost a účinnost dlouhodobého podávání tolvaptanu : komentář2017 | First Faculty of Medicine
- Research Report University Hospital for clinical assessment AIN457B2201E1Publication without faculty affiliation
- Research Report University Hospital clinical trial 101MS326Publication without faculty affiliation
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. IgPro20_3004Publication without faculty affiliation
- Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab2021 | Third Faculty of Medicine
- Long‑term effect of siponimod on MRI outcomes in patients with secondary‑progressive multiple sclerosis2022 | Faculty of Medicine in Hradec Králové
- Predictors of long-term outcomes in patients treated with riociguat for chronic thromboembolic pulmonary hypertension: data from the CHEST-2 open-label, randomised, long-term extension trial2016 | First Faculty of Medicine
- Riociguat for the treatment of chronic thromboembolic pulmonary hypertension: a long-term extension study (CHEST-2)2015 | First Faculty of Medicine
- Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial2016 | First Faculty of Medicine
- Efficacy and safety of riociguat in combination therapy for patients with pulmonary arterial hypertension (PATENT studies)2020 | First Faculty of Medicine
- Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients2014 | First Faculty of Medicine
- Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program2021 | First Faculty of Medicine